Minimal residual disease (MRD)–negative conversion rates improved with the use of subcutaneous daratumumab (Darzalex) plus lenalidomide (Revlimid) maintenance vs lenalidomide alone among those with newly diagnosed multiple myeloma and MRD positivity ... [8530 chars].. reed more
